Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Laurie H Sehn, Kai Hübel, Stefano Luminari, Christian W Scholz, Antonio Salar, Shankara Paneesha, Björn Engelbrekt Wahlin, Panayiotis Panayiotidis, Hui-Peng Lee, Ana Jiménez-Ubieto, Juan-Manuel Sancho, Tae Min Kim, Eva Domingo Domenech, Takahiro Kumode, Christina Poh, Catherine Thieblemont, Dries Deeren, Edwin de Wit, Michael Arbushites, Irene Vassallo, Marek Trneny, Björn Engelbrekt Wahlin, Tae Min Kim, Eva Domingo Domenech

Open source

DOI: 10.1016/s0140-6736(25)01778-7
Published: 2026-01
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-01778-7,
  title = {Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial},
  author = {Laurie H Sehn and Kai Hübel and Stefano Luminari and Christian W Scholz and Antonio Salar and Shankara Paneesha and Björn Engelbrekt Wahlin and Panayiotis Panayiotidis and Hui-Peng Lee and Ana Jiménez-Ubieto and Juan-Manuel Sancho and Tae Min Kim and Eva Domingo Domenech and Takahiro Kumode and Christina Poh and Catherine Thieblemont and Dries Deeren and Edwin de Wit and Michael Arbushites and Irene Vassallo and Marek Trneny and Björn Engelbrekt Wahlin and Tae Min Kim and Eva Domingo Domenech},
  year = {2026},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(25)01778-7},
  url = {https://doi.org/10.1016/s0140-6736(25)01778-7}
}

RIS

TY  - JOUR
TI  - Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
AU  - Laurie H Sehn
AU  - Kai Hübel
AU  - Stefano Luminari
AU  - Christian W Scholz
AU  - Antonio Salar
AU  - Shankara Paneesha
AU  - Björn Engelbrekt Wahlin
AU  - Panayiotis Panayiotidis
AU  - Hui-Peng Lee
AU  - Ana Jiménez-Ubieto
AU  - Juan-Manuel Sancho
AU  - Tae Min Kim
AU  - Eva Domingo Domenech
AU  - Takahiro Kumode
AU  - Christina Poh
AU  - Catherine Thieblemont
AU  - Dries Deeren
AU  - Edwin de Wit
AU  - Michael Arbushites
AU  - Irene Vassallo
AU  - Marek Trneny
AU  - Björn Engelbrekt Wahlin
AU  - Tae Min Kim
AU  - Eva Domingo Domenech
PY  - 2026
JO  - The Lancet
DO  - 10.1016/s0140-6736(25)01778-7
UR  - https://doi.org/10.1016/s0140-6736(25)01778-7
ER  -

APA

Sehn, L. H., Hübel, K., Luminari, S., Scholz, C. W., Salar, A., Paneesha, S., Wahlin, B. E., Panayiotidis, P., Lee, H., Jiménez-Ubieto, A., Sancho, J., Kim, T. M., Domenech, E. D., Kumode, T., Poh, C., Thieblemont, C., Deeren, D., Wit, E. D., Arbushites, M., Vassallo, I., Trneny, M., Wahlin, B. E., Kim, T. M., & Domenech, E. D. (2026). Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)01778-7

Source records

crossref · retrieved 2026-09-27T04:04:39.213Z